Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

New study shows that targeting an oft-drugged family of cell membrane receptors with biased modulators can expand potential ...

An international research team led by the Medical University of Vienna has demonstrated for the first time that thyroid ...

PHOENIX — The oral medication resmetirom significantly improved liver stiffness and reduced portal hypertension in metabolic ...

Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...

Specifically, in the PRRT-naive cohort, the ORR reached 60%, while 34.1% of patients showed stable disease. Combining these ...

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune ...

About one-third of all drugs approved by the Food and Drug Administration target the largest family of cell membrane receptors called G ...

Q3 2025 Earnings Call Transcript October 28, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.11, ...

Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.

Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor ...